Thomas Leonard
Directeur/Membre du Conseil chez NUGENEREX IMMUNO-ONCOLOGY, INC.
Postes actifs de Thomas Leonard
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| NUGENEREX IMMUNO-ONCOLOGY, INC. | Directeur/Membre du Conseil | - | - |
| Independent Dir/Board Member | - | - |
Historique de carrière de Thomas Leonard
Anciens postes connus de Thomas Leonard
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
Formation de Thomas Leonard
| New York University | Graduate Degree |
| St. John's University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
| Graduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Entreprise privées | 1 |
|---|---|
NuGenerex Immuno-Oncology, Inc.
 NuGenerex Immuno-Oncology, Inc. BiotechnologyHealth Technology NuGenerex Immuno-Oncology, Inc. is an oncology company focuses on the modulation of the immune system to treat cancer. It develops immunotherapeutic products and vaccines based on proprietary, patented platform technology, Ii-Key. The Ii-Key is a peptide derived from the major histocompatibility complex (MHC) class II associated invariant chain that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. The company was founded on October 8, 1993 and is headquartered in Miramar, FL. | Health Technology |
- Bourse
- Insiders
- Thomas Leonard
- Expérience
